TYMP and neoplasm: TYMP-targeted therapy using small-molecule TYMP inhibitors (i.e., trifluridine, tipiracil, or TAS-102) has been shown to cause tumor regression in a large number of preclinical gastrointestinal tumor models (20–23) and is under evaluation as monotherapy (NCT03974594) and in combination with other therapeutic regimens in a large number of clinical trials (24–26).